BioMed Research International / 2014 / Article / Tab 4

Review Article

MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients’ Samples

Table 4

MicroRNAs associated with PCa therapy.

ReferencesSample typeTherapymiRs deregulatedmiRs selected as candidates

Josson et al. (2008) [107]LnCaP and
LnCaP C4-2B
Radiation therapy6 downregulatedmiR-521

Huang et al. (2013) [110]PC3 radiation
resistant cells
Radiation therapy1 upregulatedmiR-95

Ribas et al. (2009) [85]LNCaP and LAPC-4Hormone therapyOverexpressedmiR-21 

Ottman et al. (2014) [113]LnCap CDX
sensitive cells
non-sensitive cells
Androgen deprivation-therapy and casodex21 upregulated
22 downregulated  

Lehmusvaara et al. (2013) [114]28 tumor tissues ( goserelin-treated patients bicalutamide-treated patients no treated-patients)   Endocrine treatment 10 deregulated miR-9 and miR-17 

Zhang et al. (2011) [88]Serum samples from localized PCa (), ADPC (), CRPC DTX treated () and BPH ()Docetaxel1 upregulatedmiR-21 (in CRPC docetaxel resistant)

Puhr et al. (2012) [116]PC3 docetaxel-resistant cellsDocetaxel2 downregulatedmiR-200c, miR-205

Lin et al. (2014) [118]  
Serum and plasma samples from CRPC PCa () before and after therapyDocetaxel46 deregulated miR-200c, miR-200b, miR-146a,  
miR-222, miR-301b, miR-20a

Kojima et al. (2010) [119]PC3 paclitaxel-resistant cellsPaclitaxel1 downregulatedmiR-34a

Fujita et al. (2010) [121]PC3 and DU145Paclitaxel1 downregulatedmiR-148

PCa: prostate cancer; ADPC: androgen dependent prostate cancer; CRPC: castration resistant prostate cancer; BPH: benign prostatic hyperplasia; DTX: docetaxel; CDX: casodex.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.